Visual Impairment News and Research

Latest Visual Impairment News and Research

AER changes journal name to Insight: Research and Practice in Visual Impairment and Blindness

With its mission of providing insight into issues surrounding blindness, the journal of the Association for Education and Rehabilitation of the Blind and Visually Impaired (AER) will now express that vision in its name. Insight: Research and Practice in Visual Impairment and Blindness has been the journal's new title as of January 1, 2011.

20 Jan 2011

EDMA to endorse the campaign on Hypoparathyroidism

On the occasion of the World Hypoparathyroidism Awareness Day 2011, EDMA, the European Diagnostic Manufacturers Association, highlights the crucial role the In Vitro Diagnostic (IVD) industry can play to effectively testing this rare endocrine condition.

5 Jan 2011

QLT's oral synthetic retinoid granted orphan drug designation for treatment of Leber Congenital Amaurosis

QLT Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for QLT091001, its oral synthetic retinoid, for the treatment of Leber Congenital Amaurosis (LCA). LCA is an inherited progressive retinal degenerative disease that leads to retinal dysfunction and visual impairment beginning at birth. QLT091001 is an orally administered synthetic retinoid replacement for 11-cis-retinal, which is a key biochemical component of the visual retinoid cycle.

8 Dec 2010

FDA grants QLT's QLT091001 orphan drug designation for treatment of Retinitis Pigmentosa

QLT Inc. today announced that QLT091001, the Company's oral synthetic retinoid, has been granted orphan drug designation for the treatment of Retinitis Pigmentosa (RP) from the U.S. Food and Drug Administration (FDA). This follows the FDA grant of orphan drug designation for QLT091001 for the treatment of Leber Congenital Amaurosis (LCA) also on December 7, 2010.

8 Dec 2010

Early eye exam can save sight and prevent a life time disability

Jennifer Hartman had no idea her child had a significant vision problem. The day after her daughter's sixth birthday, after an eye exam, she was diagnosed as being legally blind in one eye with a condition called amblyopia or lazy eye.

1 Dec 2010

Phase 3 trial: TYSABRI improves vision in MS patients

Results recently presented from a study of multiple sclerosis (MS) patients taking TYSABRI (natalizumab) are supported by a Canadian woman's improved vision since starting the therapy.

25 Nov 2010

QLT expands QLT091001 Phase 1b LCA study to include patients with Retinitis Pigmentosa

QLT Inc. today announced expansion of the Phase 1b clinical proof-of-concept study of QLT091001 in the treatment of Leber Congenital Amaurosis (LCA) to include patients with Retinitis Pigmentosa (RP), a set of hereditary retinal diseases demonstrating clinical features similar to LCA.

28 Oct 2010

Cataract surgery also reduces car crashes

Cataract surgery not only improves vision and quality of life for older people, but is also apparently a way to reduce the number of car crashes. The research will be presented today's at the Scientific Program of the 2010 American Academy of Ophthalmology (AAO) - Middle East-Africa Council of Ophthalmology (MEACO) Joint Meeting.

20 Oct 2010

Falls are the leading cause of ER visits and unintentional home injury deaths

If you or someone you know has been treated in the emergency department recently after suffering a fall, you are not alone. Unintentional falls are the leading injury-related reason for why people seek emergency care, with almost 9 million visits occurring each year, according to the latest data from the Centers for Disease Control and Prevention.

20 Oct 2010

Cell Cure, Teva Pharmaceutical enter license option agreement for OpRegen product

BioTime, Inc., Cell Cure Neurosciences Ltd., and Hadasit Bio-Holdings Ltd. jointly announced today that Cell Cure and Teva Pharmaceutical Industries Ltd. have entered into an exclusive license option agreement to develop and commercialize Cell Cure's OpRegen product for the treatment of age-related macular degeneration (AMD).

11 Oct 2010

FDA approves OZURDEX implant for uveitis treatment

Allergan, Inc. today announced that the United States Food and Drug Administration (FDA) has approved OZURDEX (dexamethasone intravitreal implant) 0.7 mg for the treatment of non-infectious ocular inflammation, or uveitis, affecting the posterior segment of the eye.

27 Sep 2010

South Carolina optometrists provide eye, vision assessments for infants through InfantSEE

Due to the overwhelming number of children with eye and vision problems across the United States, South Carolina optometrists are devoting appointments to no-cost, comprehensive eye and vision assessments for infants between six to 12 months of age through InfantSEE.

21 Sep 2010

AstraZeneca, UCL collaborate to identify new therapeutic tools to modulate regenerative capacity of stem cells

AstraZeneca and UCL (University College London) today announced that they have entered into a collaboration to develop regenerative medicines for diabetic retinopathy (DR).

13 Sep 2010

Scientists discover gene associated with myopia

Myopia (nearsightedness) is the most common eye disorder in the world and becoming more common, yet little is known about its genetic underpinnings.Scientists at Duke University Medical Center, in conjunction with several other groups, have uncovered a gene associated with myopia in Caucasian people from several different regions, including Dutch, British and Australian subjects.

13 Sep 2010

New article examines education practices, priorities for deaf-blind children

Deaf-blind children can be isolated and disconnected from people and activities. Without individualized support, they cannot access visual and auditory information and often complete school unable to seek future education, employment, or independent living. Providing appropriate special education and related services for deaf-blind children poses unique challenges.

26 Aug 2010

ISCO to formalize eye care based stem cell therapeutic programs into Cytovis business unit

International Stem Cell Corporation, today announced that its stem cell therapeutic programs focused on protective, transparent corneas (CytoCor™) in the front of the eye and the light-sensitive retinal tissue (CytoRet™) in the back of the eye will be formalized into a new business unit, Cytovis™.

20 Aug 2010

Non-viral gene therapy delays onset of eye disease

In one of only two studies of its kind, a study from researchers at Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences at Tufts demonstrates that non-viral gene therapy can delay the onset of some forms of eye disease and preserve vision. The team developed nanoparticles to deliver therapeutic genes to the retina and found that treated mice temporarily retained more eyesight than controls.

17 Aug 2010

International Stem Cell, IBVI sign letter of intent concerning funding, establishment of ISCO India

International Stem Cell Corporation, www.internationalstemcell.com, and Insight Bioventures India Private Limited, announced today that they have signed a letter of intent concerning funding and establishment of an Indian affiliate of ISCO. The goal is to establish world-class development and manufacturing operations for ISCO's research and pharmaceutical products in India, including its Lifeline Cell Technology research products and human corneal tissue, CytoCor, for treatment of corneal vision impairment and testing of chemicals.

20 Jul 2010

ISCO and Sankara Nethralaya collaborate to develop "CytoCor" stem cell-derived corneal tissue

International Stem Cell Corporation and Sankara Nethralaya, announced today commencement of a collaboration to develop ISCO's "CytoCor™" stem cell-derived corneal tissue. The goal is to use CytoCor to treat corneal blindness and vision impairment. "This is one more step in ISCO's stated plan of building its portfolio of therapeutic agents through strategic alliances throughout the world," said Chairman, Ken Aldrich.

7 Jul 2010

FDA approves IMT to improve vision in patients with end-stage AMD

The U.S. Food and Drug Administration today announced it has approved the Implantable Miniature Telescope to improve vision in some patients with end-stage age-related macular degeneration.

7 Jul 2010

Visual Impairment News and Research

Latest Visual Impairment News and Research

AER changes journal name to Insight: Research and Practice in Visual Impairment and Blindness

EDMA to endorse the campaign on Hypoparathyroidism

QLT's oral synthetic retinoid granted orphan drug designation for treatment of Leber Congenital Amaurosis

FDA grants QLT's QLT091001 orphan drug designation for treatment of Retinitis Pigmentosa

Early eye exam can save sight and prevent a life time disability

Phase 3 trial: TYSABRI improves vision in MS patients

QLT expands QLT091001 Phase 1b LCA study to include patients with Retinitis Pigmentosa

Cataract surgery also reduces car crashes

Falls are the leading cause of ER visits and unintentional home injury deaths

Cell Cure, Teva Pharmaceutical enter license option agreement for OpRegen product

FDA approves OZURDEX implant for uveitis treatment

South Carolina optometrists provide eye, vision assessments for infants through InfantSEE

AstraZeneca, UCL collaborate to identify new therapeutic tools to modulate regenerative capacity of stem cells

Scientists discover gene associated with myopia

New article examines education practices, priorities for deaf-blind children

ISCO to formalize eye care based stem cell therapeutic programs into Cytovis business unit

Non-viral gene therapy delays onset of eye disease

International Stem Cell, IBVI sign letter of intent concerning funding, establishment of ISCO India

ISCO and Sankara Nethralaya collaborate to develop "CytoCor" stem cell-derived corneal tissue

FDA approves IMT to improve vision in patients with end-stage AMD

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Visual Impairment News and Research

Latest Visual Impairment News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in